University of Texas Health Science Center San Antonio, USA
Title: Cardiovascular implications of incretins after SAVOR and EXAMINE in diabetes patients
Robert J Chilton, DO, is an Associate Professor of Medicine and Director of the Cardiac Catheterization Laboratory at the Audie Murphy VA/University of Texas Health Science Center at San Antonio. A fellow of the American College of Cardiology, American College of Physicians, American College of Osteopathic Internists, and American Heart Association, He also chairs the Electrophysiology Board Examination for the American Osteopathic Association. He received his Bachelor of Science degree from Philips University, Oklahoma, and his DO from the University of Osteopathic Medicine and Surgery, Iowa. He completed his internship at Wright-Patterson Air Force Base, Dayton, Ohio; his residency at the University of Oklahoma Health Science Center, Oklahoma City, Oklahoma; and a cardiology fellowship at the Wilford Hall United States Air Force Medical Center, Texas. He is board certified in internal medicine, cardiovascular disease, and electrophysiology. Over the past 20 years, He has authored numerous articles, book chapters, abstracts, and presentations on cardiology. He has lectured widely, garnering several awards including 1994 Outstanding Teacher from the University of Texas Health Science Center at San Antonio.
Recent publication of DPP-4 inhibitor trials, SAVOR have raised many questions related to cardiovascular concerns with heart failure hospitalization. The EXAMINE trial did find a significant increase in heart failure hospitalization. The macrovascular events were not reduced compared to the control arm with DPP 4 inhibitors. There were very low hypoglycemic events and no significant difference in pancreatitis between drug treatment group and controls.